Search

A recent study conducted by researchers at the University of Liverpool examined the effectiveness and cost-effectiveness of lenvatinib plus pembrolizumab as a treatment for advanced renal cell carcinoma (RCC), the most common type of kidney cancer. The study found that this treatment may increase the survival time for patients at a higher risk of disease progression compared to current NHS treatments. However, for patients at a lower risk of disease progression, the evidence is limited and only shows a potential for prolonging stable disease. The study also found that lenvatinib plus pembrolizumab is more expensive than other treatment options. The study provides valuable information for decision-making by the National Institute for Health and Care Excellence (NICE) regarding the use of lenvatinib plus pembrolizumab in the NHS. [Extracted from the article]

Researchers from Massachusetts General Hospital have developed a rapid universal dissociation protocol for human and mouse tumor tissue samples, which is crucial for single-cell RNA sequencing (scRNAseq). This protocol ensures the viability and quality of the dissociated sample, which is essential for successful generation of Gel Bead-In Emulsions (GEMs), barcoding, and sequencing. The use of scRNAseq allows for the identification of transcriptional heterogeneity in tumor specimens at the single-cell level, leading to discoveries related to immune and tumor cellular states and programs associated with clinical responses to immunotherapies and other treatments. The research was supported by the Adelson Medical Research Foundation and the Melanoma Research Alliance. [Extracted from the article]